Ozempic, Wegovy: Stopping Use Causes Fast Weight Regain
A new BMJ study reveals alarming weight regain after stopping drugs like Ozempic. Experts warn against treating them as short-term trends. Learn the facts and risks.
Category : Search result: semaglutide generics
Stopping Weight-Loss Jabs Leads to Rapid Weight Regain: BMJ
A new BMJ study reveals that discontinuing weight-loss drugs like Ozempic and Mounjaro leads to regaining all lost weight within 1.5 years. Experts advise on long-term management strategies.
Natco Pharma Sues to Revoke Novo Nordisk's Semaglutide Patent
Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
Natco Files to Revoke Novo Nordisk's Wegovy Patent in India
Hyderabad's Natco Pharma petitions Delhi High Court to revoke Novo Nordisk's semaglutide patent. The legal battle shapes India's future weight-loss drug market as 2026 patent expiry nears. Read more.
Novo Nordisk launches Wegovy weight-loss pill in US
Novo Nordisk launches oral Wegovy weight-loss drug in the US, priced at $299. The pill, approved in Dec 2025, aims to regain market share from rival Eli Lilly. UK approval expected end-2026.
Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Semaglutide Patent Expiry Creates Rs 50,000 Cr Opportunity
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
Heart Protection from Semaglutide: Key Findings for India
New data shows semaglutide reduces major heart events by 20%, independent of weight loss. This breakthrough offers new hope for India's early-onset heart disease patients. Learn more.
Weight-loss drugs poised for takeoff, cancer care expands in 2026
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
Indian Pharma Firms Eye Licensing Deals for Obesity Drugs
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
Ajanta Pharma's Semaglutide Deal Boosts Growth Prospects
Ajanta Pharma partners with Biocon to market weight-loss drug semaglutide in 26 markets. Deal expected to add ₹200 crore sales by FY28, enhancing its branded generics focus. Read more.
Obesity Drug Market in India Grows 10-Fold in 5 Years
India's anti-obesity market, now valued at over Rs 1,000 crore, is poised for explosive growth with new drugs and generics. Discover how AI and GLP-1 therapies are transforming healthcare.
Ajanta Pharma & Biocon Partner for Generic Weight Loss Drug
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
FDA Approves Daily Wegovy Pill for Weight Loss
US FDA approves Novo Nordisk's daily Wegovy pill, an oral alternative to injections. Priced from $149, it offers 14% average weight loss. Details on cost, side effects, and how it compares to rivals.
GLP-1 Drugs Show Benefits Beyond Weight Loss
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
Emcure Enters Obesity Market with Novo Nordisk's Semaglutide
Emcure Pharmaceuticals launches Poviztra, a weekly semaglutide injection for weight loss, in partnership with Novo Nordisk. Priced from ₹2,200 per week, it targets India's massive obesity market.
Bangladesh Beats India to Export Weight-Loss Drugs to Emerging Markets
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Court Rejects Ozempic Patent Extension, Boosts Generic Drug Access
Delhi High Court rejects Novo Nordisk's patent plea on semaglutide (Ozempic/Wegovy), preventing 'evergreening'. A win for affordable generics in India, but raises concerns over non-clinical misuse of weight-loss drugs. Read more.
India-Russia Summit: Key Outcomes & UPSC Insights
India & Russia sign 16 pacts, chart roadmap till 2030. Key takeaways on labour mobility, trade, defence & nuclear energy. Essential analysis for UPSC aspirants on bilateral ties, repo rate, labour codes & more.
Delhi HC sides with Dr Reddy's in semaglutide patent case
Delhi High Court rejects Novo Nordisk's plea for interim injunction against Dr Reddy's Labs over semaglutide. Court cites 'evergreening', allows DRL to export. Key ruling for diabetes drug market.
India's Drug Patent Wars: Need for Special Courts?
A recent Delhi High Court order in the Novo Nordisk vs Dr Reddy's case highlights the complexities of Indian patent litigation. We examine the system's challenges and the push for specialized IP courts.
WHO issues first global guidelines for GLP-1 obesity drugs
WHO releases its first global guideline on GLP-1 therapies for obesity, recommending drugs like semaglutide for adults with a BMI over 30. Learn about the impact, safety, and who can benefit.
Dr Reddy's Wins Delhi HC Nod to Export Semaglutide
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
Oral Ozempic 2.0: Game-Changer Weight Loss Pills
Novo Nordisk and Eli Lilly develop daily oral weight loss pills with 10-16% average weight loss in trials. Pending FDA approval, these could replace injections.
Indian Companies Set for Semaglutide Device Windfall
Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.
Michelle Obama's Weight Loss Sparks Ozempic Speculation
Michelle Obama faces Ozempic rumors after revealing slimmer frame in Annie Leibovitz photoshoot. Social media erupts with speculation despite no evidence. Read the full story.
Lupin: Undervalued Pharma Giant at 21x P/E?
Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.
OneSource Pharma Raises FY28 Revenue Target to $500M
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Page 1 of 2